Brain nitric oxide (NO) is mainly generated by neuronal NO synthase (NOS) and inducible NOS. In various cells, NO has been shown to regulate cyclooxygenase (COX), which is divided into two isoforms, COX-1 and COX-2. We previously reported that bombesin injected into the right lateral ventricle evokes the secretion of noradrenaline and adrenaline from adrenal medulla by brain COX-mediated mechanisms in rats. In the present study, we examined whether NOS is involved and which types of NOS and COX are involved in the bombesin-induced activation of central adrenomedullary outflow using urethane-anesthetized rats. 
Introduction
Nitric oxide (NO) has been recognized as a neurotransmitter or a neuromodulator in the central nervous system (Moncada et al., 1991; Pacher et al., 2007) .
NO is generated from the amino acid L-arginine by NO synthase (NOS) (Palmer et al., 1988; Moncada et al., 1991; Jaffrey and Snyder, 1995) . Brain NOS mainly consists of neuronal NOS and inducible NOS, although NOS has been divided into three isoforms: neuronal, endothelial and inducible NOS (Costa et al., 1996; Pacher et al., 2007) .
Constitutively expressed neuronal NOS is the most abundant isoform in the brain including the hypothalamus, especially the paraventricular nucleus (Vincent and Kimura, 1992) . Since the hypothalamic paraventricular nucleus has been recognized as a regulatory center of the sympathoadrenomedullary system (Swanson and Sawchenko, 1983; Jansen et al., 1995; Kenney et al., 2003) , NO may play a role in regulating the central sympatho-adrenomedullary outflow (Zhang et al., 1997; Stern, 2004) . Inducible NOS is formed in response to various cytokines and endotoxin in various cells including neurons and glial cells in the brain (Galea et al., 1992; Romero et al., 1996; Rothwell et al., 1996; Heneka and Feinstein, 2001) . We previously reported the involvement of the brain NOS in centrally administered interleukin-1 -and corticotropin-releasing factor (CRF)-induced activation of the sympathoadrenomedullary outflow using N -nitro-L-arginine methyl ester (L-NAME) (a non-selective NOS inhibitor) in rats (Murakami et al., 1996; Okada et al., 2003b) .
Cyclooxygenase (COX) is divided into two isoforms, COX-1 and COX-2. COX-1 is constitutively expressed in the majority of tissues, while COX-2 is generally undetectable or present at low levels in the resting state but is induced by various stimuli such as inflammatory cytokines (Smith et al., 1996) . However, COX-2 has also been shown to be constitutively expressed in some tissues including the brain (Breder et al., 1995; Hetu and Riendeau, 2005) .
We have already reported the involvement of brain COX in the bombesin-, interleukin-1 -and CRF-induced activation of sympatho-adrenomedullary outflow using indomethacin (a non-selective COX inhibitor) in rats (Okuma et al., 1996; Murakami et al., 1996; Yokotani et al., 2001) .
Centrally administrated bombesin has been shown to evoke the secretion of both noradrenaline and adrenaline from the adrenal medulla by brain COX-mediated mechanisms in rats, since the peptide-induced responses were abolished by central pretreatment with indomethacin and bilateral adrenalectomy in rats (Okuma et al., 1996; Yokotani et al., 2005) . The adrenal secretion of both catecholamines was 6 also demonstrated in the centrally administered argininevasopressin-and histamine-induced responses in rats (Okada et al., 2003a; Shimizu et al., 2006; Yamaguchi-Shima et al., 2007) . In the present study, therefore, we examined whether NOS is involved and which types of NOS and COX are involved in the bombesin-induced activation of central adrenomedullary outflow with regard to the isoforms of NOS and COX, using urethane-anesthetized rats.
Materials and methods

Experimental procedures
Male Wistar rats weighing about 350 g were maintained in an air-conditioned room at 22-24°C under a constant day-night rhythm for more than 2 weeks and given food (laboratory chow, CE-2; Clea Japan, Hamamatsu, Japan) and water ad libitum. Under urethane anesthesia (1.0 g/kg, i.p.), the femoral vein was cannulated for infusion of saline (1.5 ml/h), and the femoral artery was cannulated for collecting blood samples. After these procedures, animals were placed in a stereotaxic apparatus, as explained in our previous papers (Yokotani et al., 1995; Shimizu et al., 2004) . The skull was drilled for administration of test substances into the right lateral ventricle using a stainless-steel cannula (0.3 mm outer diameter). The stereotaxic coordinates of the tip of the cannula were as follows (in mm): AP -0.8, L 1.5, V 4.0 (AP, anterior from the bregma; L, lateral from the midline; V, below the surface of the brain), according to the rat brain atlas (Paxinos and Watson, 1986) . Four hours were allowed to elapse before the start of each experiment with the application of blocking reagent or vehicle-1.
Bombesin dissolved in filtered saline was slowly administered intracerebroventricularly (i.c.v.) in a volume of 10 l/animal using a 25-l Hamilton syringe. 7- Nitroindazole, ketoprofen, 
N,N-dimethylformamide (DMF) were i.c.v. administered in a volume of 3 l/animal using a 10-l Hamilton syringe. L-NAME, S-ethylisothiourea and cycloheximide dissolved in filtered saline were i.c.v. administered in a volume of 5 l/animal using a 10-l Hamilton syringe. Where blocking reagents were used, bombesin was i.c.v. administered 30 min after the application of L-NAME, S-ethylisothiourea, 7-nitroindazole, ketoprofen or NS-398, but 120 min after the application of cycloheximide due to its slightly elevating effect on the basal plasma levels of catecholamines. Each animal received only one dose of blocking reagents or vehicles. Correct placement of the cannula was confirmed at the end of each experiment by verifying that a blue dye, injected through the cannula, had spread throughout the entire ventricular system. All experiments were conducted in compliance with the guiding principles for the care and use of laboratory animals approved by Kochi University.
Measurement of plasma catecholamines
Blood samples (250 l) were collected through an arterial catheter and were preserved on ice during experiments. Plasma was prepared immediately after the final sampling. Catecholamines in the plasma were extracted by the method of Anton and Sayre (1962) with a slight modification and were assayed electrochemically with high performance liquid chromatography (HPLC) (Shimizu et al., 2004) . Briefly, after centrifugation, the plasma (100 l) was transferred to a centrifuge tube containing 30 mg of activated alumina, 2 ml of twice deionized water, 1 ml of 1.5 M Tris Buffer (pH 8.6) containing 0.1 M disodium EDTA and 1 ng of 3,4-dihydroxybenzylamine as an internal standard. The tube was shaken for 10 min and the alumina was washed three times with 4 ml of ice-cold twice deionized water. Then, catecholamines adsorbed onto the alumina were eluted with 300 l of 4% acetic acid containing 0.1 mM disodium EDTA.
A pump (EP-300: Eicom, Kyoto, Japan), a sample injector (Model-231XL; Gilson, Villiers-le-Bel, France) and an electrochemical detector (ECD-300: Eicom) equipped with a graphite electrode were used with HPLC. Analytical conditions were as follows: detector, +450 mV potential against an Ag/AgCl reference electrode; column, Eicompack CA-50DS, 2.1 x 150 mm (Eicom); mobile phase, 0.1 M NaH 2 PO 4 -Na 2 HPO 4 buffer (pH 6.0) containing 50 mg/l disodium EDTA, 0.75 g/l 1-octanesulfate sodium and 15% methanol at a flow of 0.18 ml/min; injection volume, 40 l. The amount of catecholamine in each sample was calculated using the peak height ratio relative to that of 3,4-dihydroxybenzylamine. By this assay, coefficients of variation for intra-and inter-assay were 3.0% and 3.7%, respectively, and 0.5 pg of noradrenaline and adrenaline was accurately determined.
Treatment of data and statistics
The area under the curve (AUC) was used to compare the 
Compounds
The following drugs were used: synthetic bombesin (Peptide Institute, Osaka, Japan); cycloheximide (MP Biomedicals, Solon, OH, U.S.A.); L-NAME hydrochloride (Sigma Aldrich Fine Chemicals, St. Louis, MO, U.S.A.); Sethylisothiourea hydrobromide, 7-nitroindazole and NS-398 (Cayman Chemical, Ann Arbor, MI, U.S.A.); ketoprofen (Wako, Osaka, Japan). All other reagents were of the highest grade available (Nacalai Tesque, Kyoto, Japan).
Results
Effects of L-NAME, 7-nitroindazole and Sethylisothiourea on the centrally administered bombesininduced elevation of plasma catecholamines
Treatments with vehicle-1 (5 l saline/animal, i.c.v.) and vehicle-2 (10 l saline/animal, i.c.v.) followed by blood sampling six times over a 120-min period had no effect on the basal plasma levels of noradrenaline and adrenaline ( Fig. 1 ).
Since we previously reported that bombesin (0.1, 1 and 10 nmol/animal, i.c.v.) elevated plasma levels of both catecholamines in a dose-dependent manner (Okuma et al., 1996) , we used the dose of 1 nmol/animal in the present experiment. The administered bombesin rapidly increased plasma levels of noradrenaline and adrenaline (adrenaline > noradrenaline) (Fig. 1) . These responses reached a maximum 30 min after administration of bombesin and then declined to near basal levels. However, intravenous administration of bombesin (1 nmol/animal) had no effect on the plasma levels of both catecholamines (data not shown).
Pretreatment with L-NAME (a non-selective NOS inhibitor) [1.11 mol (300 g)/animal, i.c.v.] had no effect on the basal plasma levels of both catecholamines (Fig. 1) . L-NAME effectively attenuated the bombesin- effectively attenuated the bombesin-induced noradrenaline response, but had no effect on the adrenaline response induced by the peptide (Fig. 2 ).
Pretreatment with S-ethylisothiourea (an inducible NOS
inhibitor) [27 nmol (5 g)/animal, i.c.v.] had no effect on the basal plasma levels of noradrenaline and adrenaline (Fig. 3 ). S-Ethylisothiourea had no effect on the bombesin-induced noradrenaline response, but effectively attenuated the bombesin-induced adrenaline response in a dose-dependent manner [2.7 and 27 nmol (0.5 and 5 g)/animal, i.c.v.] (Fig. 3) . (Fig. 4) . 
Effect of cycloheximide on the centrally administered bombesin-induced elevation of plasma catecholamines
Effects of ketoprofen and NS-398 on the centrally administered bombesin-induced elevation of plasma catecholamines
Discussion
In the present experiments, we examined whether brain NOS is involved in the centrally administered bombesininduced elevation of plasma noradrenaline and adrenaline using L-NAME, a non-selective NOS inhibitor (Gross et al., 1990 ). L-NAME effectively attenuated the bombesin-induced elevation of both catecholamines, indicating the involvement of brain NOS in the bombesin-induced secretion of noradrenaline and adrenaline from the adrenal medulla in rats. Then, we examined which type of NOS is involved in the bombesin-induced responses using 7-nitroindazole and Sethylisothiourea.
7-Nitroindazole is a potent and selective inhibitor of neuronal NOS with a Ki value of 0.09 M in purified porcine brain (Mayer et al., 1994) and with a Ki value of 1.6 M in bovine brain (Wolff and Gribin, 1994) . The reagent decreased NO production in the rat cerebellum and hippocampus (Babbedge et al., 1993; Bush and Pollack, 2001) , and prevented neuronal NOS-derived NO-mediated brain damage after hypoxia in the developing brain of the chick embryo (Giusti et al., 2008) . We previously reported that the central pretreatment with 7-nitroindazole had no effect on the centrally administered interleukin-1 -induced release of noradrenaline from sympathetic nerves in rats (Murakami et al., 2002) . In the present experiment, however, 7-nitroindazole effectively attenuated the bombesin-induced elevation of plasma noradrenaline, but not adrenaline, suggesting the involvement of brain neuronal NOS in the bombesin-induced secretion of noradrenaline from the adrenal medulla in rats. The actual values for noradrenaline and adrenaline at 0 min were 117±15 and 127±27 pg/ml in the group pretreated with vehicle-1 (n=10); 84±13 and 57±26 pg/ml in the group pretreated with L-NAME (0.37 mol/animal) (n=6); 110±20
S-Ethylisothiourea
and 126±26 pg/ml in the group pretreated with L-NAME (1.11 mol/animal) (n=12), respectively. 
